title: Improvement of LDL-C laboratory values achieved by participation in a cardiac or diabetes disease management program.
abstract: Poor lipid control is a risk factor for cardiovascular diseases and diabetes complications. Frequently, however, patients with these diseases do not achieve blood lipid levels recommended by current standards of care. A retrospective study of 67,244 members eligible for disease management (DM) was initiated to evaluate the ability of interventions to promote improvement in low-density lipoprotein cholesterol (LDL-C) laboratory values for people with cardiovascular diseases or diabetes. The baseline trend in improving LDL-C values in the absence of DM was established. A two-year period prior to the start of the DM intervention was examined to measure the mean percent change in LDL-C values that was occurring in the population. The mean percent change observed for this pre-intervention group was then compared to the change in LDL-C values observed during the DM study period. A significant reduction in elevated LDL-C values (F-test; p < 0.0001) was observed for members who participated in the DM interventions, even when elevated LDL-C was defined as low as > or =70 mg/dL. Members with LDL-C values within threshold limits maintained these levels during the DM program. The significant reduction in elevated LDL-C values and maintenance of optimal values (< 100 mg/dL) was observed over the course of 3 years of participation in a DM program. A subset of the population also was examined to assess the impact of telephone intervention on reducing elevated LDL-C values. A significant relationship between receiving care calls and reduction in elevated LDL-C levels was observed; members who received calls achieved up to a 32.5% relative reduction in elevated LDL-C values compared to members who did not receive calls. In conclusion, these findings demonstrate the ability of DM interventions to assist a large, geographically diverse member population in reducing a clinical laboratory value.
authors.affiliation: Healthways, Inc., Nashville, Tennessee 37215, USA. patty.orr@healthways.com
authors.forename: Patty
authors.initials: P
authors.lastname: Orr
authors.forename: Adam
authors.initials: A
authors.lastname: Hobgood
authors.forename: Sadie
authors.initials: S
authors.lastname: Coberley
authors.forename: Patricia
authors.initials: P
authors.lastname: Roberts
authors.forename: Gerrye
authors.initials: G
authors.lastname: Stegall
authors.forename: Carter
authors.initials: C
authors.lastname: Coberley
authors.forename: James
authors.initials: J
authors.lastname: Pope
mesh_terms: D002318:Cardiovascular Diseases / Q000097:blood / Q000517:prevention & control*; D008078:Cholesterol, LDL / Q000097:blood*; D003920:Diabetes Mellitus / Q000097:blood / Q000517:prevention & control*; D006801:Humans; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D008078:Cholesterol, LDL